Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
NHS England and NHS Improvement (NHSE&I) have today (11th August 2020) issued an updated Standard Operating Procedure (SOP) for community pharmacies in relation to the COVID-19 pandemic. In the first update since March, NHSE&I has removed the flexible opening provision that allowed pharmacies to close their doors to the public for up to 2.5 hours...
In June 2020 Professor David Wright published the findings of his independent review into community pharmacy contractor representation and support. The review looked at the workings of LPCs and PSNC and it set out 33 recommendations for the future. LPCs and PSNC met in July to discuss the findings of the review, and last night...
The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Fluoxetine 40mg capsules (SSP06). SSP06 for Fluoxetine 40mg capsules was previously expected to expire on 10th August but the end date has been further extended to 4th September 2020. This expiry date may be brought forward...
Following the recent supply problems for the Evorel range of products, Theramex have provided this further update. ‘Following the acquisition of Evorel by Theramex in October 2019, we have worked tirelessly with multiple manufacturing partners to resupply the product in the UK market. Since February 2020, we have produced nearly 750,000 packs across the Evorel...
An update on the new flexible approaches being considered for support the provision of the flu vaccination service has been released. Contractors must note that the changes PSNC is seeking to the flu vaccination service, described in the update, have not yet been agreed and may never be agreed. On 3rd July 2020, PSNC published...
The Department of Health and Social Care (DHSC) has today granted three additional price concessions for prescriptions dispensed and submitted for payment in July 2020 only. Following the publication of the July final price concession update on 30th July 2020, PSNC made an additional application for three further price concessions. This was based on feedback received from...
Update 07/08/2020 resupply date now expected end Sept 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sulfasalazine 250mg/5ml oral suspension sugar free (Rosemont) . Sulfasalazine 250mg/5ml oral suspension sugar free (Rosemont) is out of stock until August 2020. Sulfasalazine 500mg tablets remain available. Some specials manufacturers are able...
Department of Health and Social Care (DHSC) has issued a medicine supply notification for Pethidine 50mg tablets Martindale are out of stock of Pethidine 50mg tablets Supplies are currently available from Teva although they will be out of stock by the end of August. There are no alternative suppliers. Neither company are currently able to...
An initial outline of requirements for Part 2 of the 2020/21 Pharmacy Quality Scheme (PQS) has been released. On 13th July 2020, PSNC informed contractors that a new PQS for the first part of 2020/21 had been launched. The focus of the first part of the scheme was to ensure community pharmacy contractors and their...
NHS Digital is supporting rollout of EPS Phase 4 to many more practices to support patients in getting their medicines during what is expected to be a busy winter season for healthcare providers. Under Phase 4 electronic prescriptions become the default, thereby reducing the amount of paperwork generated and making the process more COVID-safe. Around...
Fresenius Kabi Ltd & Calea UK Ltd has informed us of an error on the bag labels for SmofKabiven extra nitrogen electrolyte free, emulsion for infusion PL 08828/0269.
This consultation asks for views on the application of AQbD principles to pharmacopoeial standards for medicinal products.
MAHs should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.
The UK Good Laboratory Practice Monitoring Authority (UK GLPMA) recognises that there are potential challenges COVID-19 will present to members of the GLP monitoring programme.
We are planning to resume on-site UK risk-based GxP inspections in September.
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Summary list of field safety notices (FSNs) from medical device manufacturers from 31 July to 07 August 2020.
Huddersfield Pharmacy Specials (HPS) is recalling the above batches of phosphates solution for infusion due to observation of precipitation in batch 500609X. The decision to recall all other batches has been made as a precautionary measure.
Department of Health and Social Care and MHRA register of licensed wholesale distribution sites (human and veterinary).
List of sites granted a manufacturer or wholesale dealer licence
Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.
List of companies in the UK who have their licence to manufacture or wholesale medicines terminated and cancelled.
Guidance for manufacturers reporting adverse incidents with these devices under the European vigilance system.
Expected time taken to process and grant a marketing authorisation or a variation to a marketing authorisation.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
Pharmaram Ltd has informed us that a specific batch of Clexane 4,000IU (40mg)/0.4ml syringes has an error on the labelling affixed to the plastic blister packaging encasing the syringe.
List of manufacturers and their medical devices which have been granted an exemption by the MHRA
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Summary list of field safety notices (FSNs) from medical device manufacturers from 27 July to 31 July 2020
Crescent Pharma Ltd has informed us that the Patient Information Leaflet (PIL) within the packs for the below batches are missing important safety relevant text changes.
Report of the ten products for which most Special Import Certificates (SIC) have been issued by VMD in the UK.
This is the hub for all the Veterinary Medicines Directorate's communications on the changes following the end of the Transition Period.
News and guidance on veterinary medicines issues affected by coronavirus (COVID-19).
Statement (effective from 1 September 2020) on temporary VMD enforcement policy under specific circumstances in response to COVID‐19.
Marketing Authorisations Information Service (MAVIS) Hub edition 115
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Relaxation of enforcement during the coronavirus (COVID-19) outbreak
Temporary change to the standard VMD guidance on Manufacturers of extemporaneous preparations for use under the cascade (ManSA).
Enforcement of Veterinary Medicines Regulations relaxed in light of enhanced precautions required by the response to coronavirus (COVID-19).
Relaxation of enforcement during the coronavirus (COVID-19) outbreak.
Residues of veterinary medicines in food 2020 surveillance results.
Legal requirement for the sale of veterinary medicines on the internet and the VMD Accredited Internet Retailer Scheme (AIRS).
We have published our independently verified Annual Report and Accounts 2019/20
The VMD is launching an exciting new opportunity for veterinary students to attend a two-week EMS placement in July 2021.
This document contains the following information: Veterinary Medicines Directorate annual report and accounts 2019 to 2020.
Licences, certificates and special rules for bringing goods into the UK from 1 January 2021.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
The Special Imports System will be unavailable on the weekend of 20 and 21 June 2020 due to essential IT maintenance .
Details of seizure notice served at Border Force, Inverness Airport following a routine search. Published in June 2020.
Companies will jointly validate novel IBD targets
Clinical trial programme resumes after safety concerns
Company will manufacture over 25% more doses than previously planned
Deals agreed with Janssen and Novavax for another 90 million doses
If approved drug would offer a more flexible option for patients
Funding will support development of novel antifungal asset olorofim
Public trial will launch today in Isle of Wight and other locations
UK biopharma company signs licensing agreement for emactuzumab
Drug has already been approved in the EU and Japan
NHS Confederation forecasts a surge in demand
Topline results published from CheckMate-649 and CheckMate-577 studies
Deal will include access to investigational menopause drug
Up to 750,000 unused testing kits to be recalled
Independent Data Monitoring Committee recommended continuing Phase IIb study
Companies will focus on HER2-positive gastric cancer
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
